selectION has established an efficient technology platform to develop highly selective peptide blockers for ion channels. Their most advanced drug candidate is si-544 which is a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases.The company is well positioned to expand its range of class-leading ion channelblockers by targeting additional potassium, sodium, calcium and chloride channels, which will lead to other clinical applications in pain management and oncology.

Biotechnology

Therapeutics

selectION

selectION's headquarters in San Diego, CA, United States

Antonius Schuh

Andreas Klostermann

Stephen Zaniboni

Cam Gallagher

Christopher Larson

Don Scifres

Fred Ramsdell

Mike Foster

Mark Benedyk

The Leadership Team at selectION is responsible for setting the strategic vision and direction of the company, guiding the development of innovative ion channel blockers. This team oversees key operational areas including finance, research and development, and corporate governance to ensure alignment with the company’s mission of advancing therapeutic solutions for TEM-driven diseases and beyond. Their expertise drives selectION's growth and success in the competitive biotechnology landscape.

Leadership Team

The Scientific Advisors team at selectION plays a critical role in guiding the research and development of innovative ion channel blockers. Utilizing their expertise in molecular biology and pharmacology, they provide strategic insights on scientific advancements, support clinical trial design, and collaborate with cross-functional teams to ensure the efficacy and safety of selectION's peptide blockers, ultimately driving the success of the company's therapeutic pipeline.

selectION

Org chart

Board & advisors

Teams

Leadership Team

Scientific Advisors

Offices

selectION

Org chart

Board & advisors

Teams

Leadership Team

Scientific Advisors

Offices

Related companies